Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.78
-0.3%		$1.70
$0.89
▼
$9.35
$31.13M0.58255,146 shs1,177 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.61
+3.6%		$12.52
$6.62
▼
$15.35
$908.35M1.351.11 million shs666,427 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00%-7.73%+7.83%+40.94%-79.77%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%-13.19%-29.96%-24.00%+19.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cel-Sci Corporation stock logo
CVM
Cel-Sci
$1.78
-0.3%		$1.70
$0.89
▼
$9.35
$31.13M0.58255,146 shs1,177 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$9.61
+3.6%		$12.52
$6.62
▼
$15.35
$908.35M1.351.11 million shs666,427 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00%-7.73%+7.83%+40.94%-79.77%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%-13.19%-29.96%-24.00%+19.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.00
N/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.78
Moderate Buy$24.71157.15% Upside

Current Analyst Ratings Breakdown

Latest MGTX and CVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$16.00
9/24/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageNeutral$16.00
9/22/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (D-) ➝ Hold (C)
9/11/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeStrong-Buy ➝ Hold
8/14/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOutperform$26.00 ➝ $27.00
8/13/2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
(Data available from 10/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/A$2.32 per shareN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$81.39M11.34N/AN/A($0.07) per share-137.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cel-Sci Corporation stock logo
CVM
Cel-Sci
-$25.41M-$9.77N/AN/AN/AN/A-250.83%-125.06%N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$114.20M$0.7113.32N/AN/A19.87%283.85%29.39%11/12/2026 (Estimated)

Latest MGTX and CVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.46N/AN/AN/A$6.95 millionN/A
8/14/2026Q3 2026
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/A-$0.47N/A-$0.47N/AN/A
8/13/2026Q2 2026
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.4583$1.71+$2.1683$1.71$0.70 million$321.43 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cel-Sci Corporation stock logo
CVM
Cel-Sci
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cel-Sci Corporation stock logo
CVM
Cel-Sci
0.35
1.48
1.42
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.46
3.76
3.76

Institutional Ownership

CompanyInstitutional Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
12.08%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%

Insider Ownership

CompanyInsider Ownership
Cel-Sci Corporation stock logo
CVM
Cel-Sci
14.06%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cel-Sci Corporation stock logo
CVM
Cel-Sci
4417.48 million15.02 millionNo Data
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
39396.04 million88.94 millionOptionable

Recent News About These Companies

Nine analysts set USD 24.71 target for MeiraGTx stock
October 18 at 1:26 AM  |  ad-hoc-news.deA
MeiraGTx: The Data Held Up, The Valuation Didn't (Rating Downgrade)
October 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4954122-meiragtx-the-data-held-up-the-valuation-didnt-rating-downgrade
Stoke Therapeutics (NASDAQ:STOK) vs. MeiraGTx (NASDAQ:MGTX) Critical Comparison
October 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31117377
MeiraGTx Holdings plc (MGTX) Stock Analysis: Unpacking the 164% Potential Upside in Genetic Medicine
October 9, 2026  |  directorstalkinterviews.comhttps://www.directorstalkinterviews.com/meiragtx-holdings-plc-mgtx-stock-analysis-unpacking-the-164-potential-upside-in-genetic-medicine/4121265817
MeiraGTx stock gained 2.08 percent on October 7 as officer sold shares
October 8, 2026  |  ad-hoc-news.deA
MeiraGTx Holdings plc (MGTX)
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/MGTX/press-releases/
MeiraGTx (NASDAQ:MGTX) Insider Stuart Naylor Sells 27,659 Shares of Company Stock
October 7, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mgtx-insider-buying-and-selling-2026-10-07/
MeiraGTx (NASDAQ:MGTX) Stock: Insider Stuart Naylor Sells 27,659 Shares
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-meiragtx-nasdaq-mgtx-stock-insider-stuart-naylor-sells-27659-shares-2026-10-06/
MeiraGTx appoints Sebulsky: 9 analysts rate MeiraGTx stock Moderate Buy
October 5, 2026  |  ad-hoc-news.deA
MeiraGTx Holdings PLC (NASDAQ:MGTX) Stock Has Consensus Target Price of $24.71 According to Brokerages
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-meiragtx-holdings-plc-nasdaq-mgtx-stock-has-consensus-target-price-of-2471-according-to-brokerages-2026-10-02/
Financial Contrast: MeiraGTx (NASDAQ:MGTX) & aTyr Pharma (NASDAQ:ATYR)
September 30, 2026  |  defenseworld.netD
Bank of America Corp DE Makes New $3.91 Million Investment in MeiraGTx Holdings PLC $MGTX
September 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-391-million-investment-in-meiragtx-holdings-plc-mgtx-2026-09-30/
MeiraGTx (NASDAQ:MGTX) Stock Rating Cut to Hold at Wall Street Zen
September 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-meiragtx-nasdaq-mgtx-stock-rating-cut-to-hold-at-wall-street-zen-2026-09-26/
MeiraGTx (NASDAQ:MGTX) Stock Lifted to Hold by The Goldman Sachs Group
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-meiragtx-nasdaq-mgtx-stock-lifted-to-hold-by-the-goldman-sachs-group-2026-09-25/
Goldman Sachs Initiates MeiraGTx at Neutral With $16 Price Target
September 24, 2026  |  marketscreener.comM
MeiraGTx Holdings plc Announces Appointment of Alan M. Sebulsky to its Board of Directors
September 23, 2026  |  marketscreener.comM
MeiraGTx names Alan Sebulsky to its board of directors
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/Board+Changes/MeiraGTx+names+Alan+Sebulsky+to+its+board+of+directors/27093539.html
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367418/0/en/meiragtx-appoints-accomplished-healthcare-portfolio-manager-alan-m-sebulsky-to-board-of-directors.html
MeiraGTx (NASDAQ:MGTX) Shares Down 4.9% - Here's Why
September 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-meiragtx-nasdaq-mgtx-shares-down-49-heres-why-2026-09-22/
MeiraGTx Holdings PLC MGTX
September 16, 2026  |  morningstar.comM
Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
August 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/graviton-bioscience-corporation-announces-publication-of-positive-ph1b-trial-results-for-gv101-tdi01-in-chronic-graft-versus-host-disease-in-signal-transduction-and-targeted-therapy-by-beijing-tide-pharmaceutical-302860706.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cel-Sci stock logo

Cel-Sci NYSEAMERICAN:CVM

$1.78 -0.01 (-0.34%)
As of 09:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$9.61 +0.33 (+3.57%)
As of 09:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas